Literature DB >> 31907197

Induction of Effective Immunity against Trypanosoma cruzi.

Tere Williams1, Ignacio Guerrero-Ros1, Yanfen Ma1, Fabiane Matos Dos Santos2, Philipp E Scherer3, Ruth Gordillo3, Aline Horta4, Fernando Macian1, Louis M Weiss1,5, Huan Huang6.   

Abstract

Chagas disease, caused by Trypanosoma cruzi, is a major public health issue. Limitations in immune responses to natural T. cruzi infection usually result in parasite persistence with significant complications. A safe, effective, and reliable vaccine would reduce the threat of T. cruzi infections; however, no suitable vaccine is currently available due to a lack of understanding of the requirements for induction of fully protective immunity. We established a T. cruzi strain expressing green fluorescent protein (GFP) under the control of dihydrofolate reductase degradation domain (DDD) with a hemagglutinin (HA) tag, GFP-DDDHA, which was induced by trimethoprim-lactate (TMP-lactate), which results in the death of intracellular parasites. This attenuated strain induces very strong protection against reinfection. Using this GFP-DDDHA strain, we investigated the mechanisms underlying the protective immune response in mice. Immunization with this strain led to a response that included high levels of gamma interferon (IFN-γ) and tumor necrosis factor alpha (TNF-α), as well as a rapid expansion of effector and memory T cells in the spleen. More CD8+ T cells differentiate to memory cells following GFP-DDDHA infection than after infection with a wild-type (WT) strain. The GFP-DDDHA strain also provides cross-protection against another T. cruzi isolate. IFN-γ is important in mediating the protection, as IFN-γ knockout (KO) mice failed to acquire protection when infected with the GFP-DDDHA strain. Immune cells demonstrated earlier and stronger protective responses in immunized mice after reinfection with T. cruzi than those in naive mice. Adoptive transfers with several types of immune cells or with serum revealed that several branches of the immune system mediated protection. A combination of serum and natural killer cells provided the most effective protection against infection in these transfer experiments.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Trypanosoma cruzizzm321990; immunity; immunization

Mesh:

Substances:

Year:  2020        PMID: 31907197      PMCID: PMC7093140          DOI: 10.1128/IAI.00908-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  A functional network of intramolecular cross-reacting epitopes delays the elicitation of neutralizing antibodies to Trypanosoma cruzi trans-sialidase.

Authors:  Tamara A Pitcovsky; Carlos A Buscaglia; Juan Mucci; Oscar Campetella
Journal:  J Infect Dis       Date:  2002-07-17       Impact factor: 5.226

Review 2.  Current status and future prospects for a vaccine against American trypanosomiasis.

Authors:  Nisha Garg; Vandanajay Bhatia
Journal:  Expert Rev Vaccines       Date:  2005-12       Impact factor: 5.217

Review 3.  Natural Killer Cell Memory.

Authors:  Timothy E O'Sullivan; Joseph C Sun; Lewis L Lanier
Journal:  Immunity       Date:  2015-10-20       Impact factor: 31.745

Review 4.  Molecular mechanisms of host cell invasion by Trypanosoma cruzi.

Authors:  Conrad L Epting; Bria M Coates; David M Engman
Journal:  Exp Parasitol       Date:  2010-06-18       Impact factor: 2.011

5.  Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance.

Authors:  K A Norris
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  NK cell activation and protection occur independently of natural killer T cells during Trypanosoma cruzi infection.

Authors:  Malcolm S Duthie; Stuart J Kahn
Journal:  Int Immunol       Date:  2005-03-31       Impact factor: 4.823

7.  The adipocyte as an important target cell for Trypanosoma cruzi infection.

Authors:  Terry P Combs; Shankar Mukherjee; Cecilia J G de Almeida; Linda A Jelicks; William Schubert; Ying Lin; David S Jayabalan; Dazhi Zhao; Vicki L Braunstein; Shira Landskroner-Eiger; Aisha Cordero; Stephen M Factor; Louis M Weiss; Michael P Lisanti; Herbert B Tanowitz; Philipp E Scherer
Journal:  J Biol Chem       Date:  2005-04-18       Impact factor: 5.157

Review 8.  The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease.

Authors:  Caroline Junqueira; Braulia Caetano; Daniella C Bartholomeu; Mariane B Melo; Catherine Ropert; Maurício M Rodrigues; Ricardo T Gazzinelli
Journal:  Expert Rev Mol Med       Date:  2010-09-15       Impact factor: 5.600

9.  Peroxiredoxins play a major role in protecting Trypanosoma cruzi against macrophage- and endogenously-derived peroxynitrite.

Authors:  Lucía Piacenza; Gonzalo Peluffo; María Noel Alvarez; John M Kelly; Shane R Wilkinson; Rafael Radi
Journal:  Biochem J       Date:  2008-03-01       Impact factor: 3.857

Review 10.  Evaluation and treatment of chagas disease in the United States: a systematic review.

Authors:  Caryn Bern; Susan P Montgomery; Barbara L Herwaldt; Anis Rassi; Jose Antonio Marin-Neto; Roberto O Dantas; James H Maguire; Harry Acquatella; Carlos Morillo; Louis V Kirchhoff; Robert H Gilman; Pedro A Reyes; Roberto Salvatella; Anne C Moore
Journal:  JAMA       Date:  2007-11-14       Impact factor: 56.272

View more
  2 in total

1.  Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi.

Authors:  Natacha Cerny; Augusto Ernesto Bivona; Andrés Sanchez Alberti; Sebastián Nicolás Trinitario; Celina Morales; Alejandro Cardoso Landaburu; Silvia Inés Cazorla; Emilio Luis Malchiodi
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

2.  Prevalence and Epitope Recognition of Anti-Trypanosoma cruzi Antibodies in Two Procyonid Species: Implications for Host Resistance.

Authors:  Guiehdani Villalobos; Claudia I Muñoz-García; Roberto Rodríguez-Cabo-Mercado; Nancy Mendoza-Bazán; Adrián Hernández-Ortiz; Claudia Villanueva-García; Fernando Martínez-Hernández; Emilio Rendón-Franco
Journal:  Pathogens       Date:  2020-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.